Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-07-11)Premium Content

Gilead Sciences Inc (GILD)

2014-10-02@05:34:13 ET
Form 144: Filing to Sell 8000 Shares of Gilead Sciences Inc (GILD) (VKR)

2014-10-01@10:21:04 ET
CorMedix Files IND Application for Neutrolin in the US (ZAX)

2014-10-01@05:52:14 ET
Form 4: Update Filing for Gilead Sciences Inc (GILD) (VKR)

2014-10-01@01:23:16 ET
Gilead: Harvoni Approved by European CHMP for the Treatment of Chronic Hepatitis C Infection in Adults (CLM)

2014-10-01@01:16:29 ET
Gilead Sciences Updates on European CHMP (CLM)

2014-09-30@09:57:17 ET
Gilead Sciences (GILD) Showing Bullish Technicals With Support At $105.32 (FBM)

2014-09-30@08:50:00 ET
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher (PRN)

2014-09-29@12:03:31 ET
Top 3 Companies in the Biotechnology Industry With the Highest Operating Margin (PDLI, GILD, ANIK) (F70)

2014-09-29@11:47:31 ET
Gilead's Phase III HIV-1 infection trials meet primary objectives (DTM)

2014-09-29@10:04:09 ET
Gilead Sciences (GILD) Breaks Through Support at $107.09 (PSM)

2014-09-29@09:35:50 ET
Gilead Sciences (GILD) Showing Support Near $105.80 (FBM)

2014-09-29@09:30:00 ET
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers, Johnson & Johnson, AbbVie and Medivation (PRN)

2014-09-28@07:10:27 ET
Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance (ZAX)

2014-09-28@07:10:23 ET
Alnylam Starts New Study on Cardiac Amyloidosis Patients (ZAX)

2014-09-26@13:24:23 ET

2014-09-26@09:08:36 ET
US Stocks Poised For Higher Open as Q2 GDP Growth Meets Views; Consumer Sentiment Seen Unchanged (MID)

2014-09-26@07:18:00 ET
European CHMP Adopts Positive Opinion for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults (BIZ)

2014-09-26@01:18:09 ET
Gilead Submits NDA to Japan's PMDA for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection (CLM)